Summary
Background. The 20210 A allele variation in the 3’ -untranslated region of the prothrombin
gene was recently identified as a risk factor as regards deep venous thrombosis. Aim.
To assess the frequency of the variation in unselected patients with a proven venous
thromboembolism (VTE). Methods. The presence of the prothrombin variation was determined
in all consecutive patients referred from July 1994 to August 1997 for a clinical
suspicion of VTE, and in whom the diagnosis was confirmed. A control group consisted
of bone marrow volunteer donors. Results. Of the 366 patients included, 17 (4.6%)
were carriers of the 20210 A allele (95% CI, 2.4% to 6.7%). The mutation was present
in 1.0% of the 400 controls. Odds ratio for having VTE in the presence of the 20210
A allele was 4.8 (95% CI, 1.5 to 19.8). Forty-six (12.5%) patients had the mutation
of the factor V gene and five (1.4%) patients shared both mutations. After excluding
the carriers of the factor V mutation, odds ratio for having VTE in the presence of
the 20210 A allele was 3.7 (95% CI, 1.1 to 13.6). Mean age at admission as well as
mean age of the first VTE episode were both significantly higher in patients free
from the two mutations studied, as compared to carriers of the 20210 A allele (p =
0.04 and 0.01, respectively). Conclusion. Our findings in a large series of patients
(1) confirm the 20210 A allele prothrombin gene as a risk factor for VTE. (2) suggest
that its association with the factor V Leiden is not uncommon.